The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
 
Julian R. Molina
No Relationships to Disclose
 
Diane M. Simeone
Consulting or Advisory Role - FibroGen
Research Funding - Biological Dynamics; Clearnote Health; Immunovia; Micronoma
Patents, Royalties, Other Intellectual Property - small royalties for my patent on pancreatic cancer stem cells also I receive an annual royalty for a textbook I edited Greenfields Textbook of Surgery
 
Caleb Joshua Smith
Travel, Accommodations, Expenses - A2 Biotherapeutics
 
Theodore H Welling
No Relationships to Disclose
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Seagen; Veru
Consulting or Advisory Role - MyCareGorithm
Travel, Accommodations, Expenses - A2Bio
 
Patrick Grierson
Employment - Walgreens (I)
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer
 
Maria Pia Morelli
No Relationships to Disclose
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Corcept Therapeutics; Exelixis; Gilead Sciences; Istari; Notch Therapeutics; Regenacy Pharmaceuticals; Tempus
Research Funding - A2 Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Bold Therapeutics (Inst); Camurus (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Tesaro/GSK (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Sandip Pravin Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Certis Oncology Solutions; Compugen; Illumina; Iovance Biotherapeutics (Inst); Lilly; Lilly; Merck; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics; Takeda (Inst); Takeda (Inst)
 
Frederick L. Locke
Consulting or Advisory Role - A2 Biotherapeutics; Allogene Therapeutics; Amgen; Bluebird Bio; Bristol-Myers Squibb; Calibr; Caribou Biosciences; Cowen; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead Company; Legend Biotech; Novartis; Pfizer; Sana Biotechnology; Umoja Biopharma
Research Funding - 2seventy bio (Inst); Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Cero Therapeutics (Inst); Kite, a Gilead Company (Inst); Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke); National Cancer Institute (R01CA244328 MPI: Locke; P30CA076292 PI: Cleveland); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy. (Inst)
Other Relationship - Data Safety Monitoring Board: Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee.
(OPTIONAL) Uncompensated Relationships - Education or Editorial Activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer
 
Wen-Kai Weng
No Relationships to Disclose
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Bayer; BMS; Eisai; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Judy G. Vong
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
 
Kirstin B. Liechty
Stock and Other Ownership Interests - A2 Biotherapeutics; Ceria Therapeutics
 
Eric Wai-Choi Ng
Employment - A2 Biotherapeutics; Amgen
Stock and Other Ownership Interests - A2 Biotherapeutics; Amgen
Travel, Accommodations, Expenses - A2 Biotherapeutics; Amgen
 
John Sutton Welch
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
Consulting or Advisory Role - Agios; Archer
Research Funding - Janssen Oncology (Inst); Notable Labs (Inst)
 
Marcela Valderrama Maus
Leadership - 2Seventy Bio Board of directors
Stock and Other Ownership Interests - 2seventy bio; Century Therapeutics; Genocea Biosciences; NexImmune; Oncternal Therapeutics; TCR2 Therapeutics
Honoraria - ArsenalBio
Consulting or Advisory Role - Adaptimmune; Agenus; Allogene Therapeutics; Arcellx; Astellas Pharma; AstraZeneca; Atara Biotherapeutics; Bayer; Bristol-Myers Squibb; Cabaletta Bio (SAB); Cellectis (SAB); Crispr Therapeutics; Genocea Biosciences; GlaxoSmithKline; In8bio (SAB); Intellia Therapeutics; Kite, a Gilead Company; Micromedicine/BendBio; NexImmune; Novartis; Oncternal Therapeutics; Sanofi; TCR2 (SAB); Tmunity Therapeutics, Inc.; WindMIL (SAB)
Speakers' Bureau - ArsenalBio
Research Funding - Kite, a Gilead Company; Novartis
Patents, Royalties, Other Intellectual Property - Multiple, owned by Massachusetts General Hospital (Inst); Novartis; Promab
Expert Testimony - Australia FPA
 
David G. Maloney
Stock and Other Ownership Interests - A2 Biotherapeutics; NAVAN Technologies
Honoraria - Bristol-Myers Squibb; Caribou Biosciences; Celgene; Genentech; Incyte; Janssen; Juno Therapeutics; Kite, a Gilead Company; Lilly; MustangBio; Novartis; Umoja Biopharma
Consulting or Advisory Role - Genentech; Member and Chair of the Lymphoma Steering Committee
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead Company (Inst); Legend Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Rights to royalties from Fred Hutch for patents licensed to Juno Therapeutics/BMS
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Member of the JCAR017-BCM-03 Scientific Steering Committee
 
William Y. Go
Leadership - A2 Biotherapeutics; APA Foundation Board and Viewpoint School Board
Stock and Other Ownership Interests - A2 Biotherapeutics; Amgen; Gilead Sciences
 
Salman Rafi Punekar
Research Funding - Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)